Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?, Neurosci Lett. 2 juin, vol.596, pp.90-107, 2015. ,
, Institut National du Cancer, 10e édition « les cancers en France, 2017.
Mechanisms involved in the development of chemotherapy-induced neuropathy, Pain Manag, vol.5, issue.4, pp.285-96, 2015. ,
Chemotherapy-induced peripheral neuropathy -diagnosis, evolution and treatment, Ginekol Pol, vol.87, issue.7, pp.516-537, 2016. ,
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy, Front Mol Neurosci, vol.10, p.174, 2017. ,
Chemotherapy-induced peripheral neuropathy: an update on the current understanding, vol.5, 2016. ,
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers, J Clin Oncol. 20 juin, vol.32, issue.18, pp.1941-67, 2014. ,
Cisplatin in cancer therapy: molecular mechanisms of action, Eur J Pharmacol, vol.740, pp.364-78, 2014. ,
Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling, Neurobiol Dis. mars, vol.9, issue.2, pp.220-253, 2002. ,
Emerging trends in understanding chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep, vol.17, p.364, 2013. ,
Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy, Expert Opin Pharmacother, vol.17, issue.4, pp.561-70, 2016. ,
Toxicity of platinum compounds, Expert Opin Pharmacother. juin, vol.4, issue.6, pp.889-901, 2003. ,
Amifostine in clinical oncology: current use and future applications, Anticancer Drugs. mars, vol.13, issue.3, pp.181-209, 2002. ,
Auditory toxicity effects of longterm cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients, J Surg Oncol, vol.16, issue.2, pp.111-134, 1981. ,
Comparative adverse effect profiles of platinum drugs. Drug Saf, vol.13, pp.228-272, 1995. ,
Cisplatin-induced vomiting depends on circadian timing, Chronobiol Int. sept, vol.18, issue.5, pp.851-63, 2001. ,
Risk of leukemia after platinum-based chemotherapy for ovarian cancer, N Engl J Med. 4 févr, vol.340, issue.5, pp.351-358, 1999. ,
The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors, Cancer. 1 avr, vol.91, issue.7, pp.1297-303, 2001. ,
Quantitation of cisdiamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy, J Clin Invest. févr, vol.77, issue.2, pp.545-50, 1986. ,
Chemotherapy-induced peripheral neurotoxicity (CIPN): an update, Crit Rev Oncol Hematol. avr, vol.82, issue.1, pp.51-77, 2012. ,
Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle, J Clin Invest. 15 juin, vol.101, issue.12, pp.2842-50, 1998. ,
Cellular processing of platinum anticancer drugs, Nat Rev Drug Discov. avr, vol.4, issue.4, pp.307-327, 2005. ,
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention, Neuro-Oncol. sept, vol.14, issue.4, pp.45-54, 2012. ,
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature, Cancer Manag Res, vol.6, pp.135-182, 2014. ,
Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy, J Neurosci Off J Soc Neurosci. 29 août, vol.27, issue.35, pp.9451-9458, 2007. ,
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review, Front Pharmacol, vol.8, p.86, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01682157
Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy, Toxicology. 27 janv, vol.291, issue.1-3, pp.1-9, 2012. ,
Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies, Brain J Neurol. avr, vol.130, pp.1076-88, 2007. ,
Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies, Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. févr, vol.12, issue.2, pp.81-91, 2010. ,
Severe, disabling neurologic toxicity following cisplatin retreatment, Ann Pharmacother. févr, vol.29, issue.2, pp.134-141, 1995. ,
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies, Cancer, vol.54, issue.7, pp.1269-75, 1984. ,
Toxic neuropathy in patients with pre-existing neuropathy, Neurology. 28 janv, vol.60, issue.2, pp.337-377, 2003. ,
The enteric nervous system III: a target for pharmacological treatment, Pharmacol Toxicol. juill, vol.93, issue.1, pp.1-13, 2003. ,
Lhermitte's sign as a complication of cisplatincontaining chemotherapy for testicular cancer, Cancer Treat Rep. juill, vol.70, issue.7, pp.905-912, 1986. ,
Carboplatinassociated ototoxicity in children with retinoblastoma, J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.30, issue.10, pp.1034-1075, 2012. ,
Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer, Dis Esophagus Off J Int Soc Dis Esophagus. déc, vol.28, issue.8, pp.782-789, 2015. ,
Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies, J Neurol. déc, vol.252, issue.12, pp.1459-64, 2005. ,
Particular aspects of platinum compounds used at present in cancer treatment, Crit Rev Oncol Hematol. juin, vol.42, issue.3, pp.317-342, 2002. ,
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/-ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide, Anticancer Res, vol.20, issue.5C, pp.3767-73, 2000. ,
Application of the area under the curve of carboplatin in predicting toxicity and efficacy, Cancer Treat Rev. déc, vol.24, issue.6, pp.407-421, 1998. ,
Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy, J Neurol Neurosurg Psychiatry. mai, vol.64, issue.5, pp.667-676, 1998. ,
Prolonged oxaliplatin exposure alters intracellular calcium signaling: a new mechanism to explain oxaliplatin-associated peripheral neuropathy, Clin Colorectal Cancer. juin, vol.10, issue.2, pp.126-159, 2011. ,
A review on oxaliplatin-induced peripheral nerve damage, Cancer Treat Rev. juin, vol.34, issue.4, pp.368-77, 2008. ,
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat, Eur J Cancer Oxf Engl, vol.37, issue.18, pp.2457-63, 1990. ,
Oxaliplatin: a review in the era of molecularly targeted therapy, Curr Oncol Tor Ont. janv, vol.18, issue.1, pp.18-25, 2011. ,
Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer, Drugs, vol.63, pp.2127-56, 2003. ,
Severe anaphylactic reactions to oxaliplatin, Eur J Cancer Oxf Engl, vol.34, issue.8, pp.1297-1305, 1990. ,
A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltagegated sodium channels, J Neurophysiol. mai, vol.85, issue.5, pp.2293-2300, 2001. ,
Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, Cancer Treat Rev. déc, vol.350, issue.8, pp.711-714, 2004. ,
Persistent neuropathy after treatment with cisplatin and oxaliplatin, Acta Oncol Stockh Swed, vol.48, issue.6, pp.832-873, 2009. ,
Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up, Eur Neurol, vol.56, issue.1, pp.13-19, 2006. ,
A possible link of oxaliplatin-induced neuropathy with potassium channel deficit, Muscle Nerve. mars, vol.45, issue.3, pp.403-414, 2012. ,
Taxane-Induced Peripheral Neurotoxicity, Toxics. 28 avr, vol.3, issue.2, pp.152-69, 2015. ,
Paclitaxel in cancer therapy, Expert Opin Pharmacother. juin, vol.3, issue.6, pp.755-66, 2002. ,
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects, Cancer Treat Rev. sept, vol.21, issue.5, pp.463-78, 1995. ,
Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACTtaxane), Cancer. 15 août, vol.98, issue.4, pp.822-853, 2003. ,
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion, J Clin Oncol Off J Am Soc Clin Oncol. déc, vol.12, issue.12, pp.2654-66, 1994. ,
Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel, Cancer Chemother Pharmacol, vol.44, issue.2, pp.138-180, 1999. ,
Clinical toxicities encountered with paclitaxel (Taxol), Semin Oncol. août, vol.20, issue.4, pp.1-15, 1993. ,
, Neurotoxicity of Taxol. J Natl Cancer Inst Monogr, issue.15, pp.107-122, 1993.
The taxanes: toxicity and quality of life considerations in advanced ovarian cancer, Br J Cancer. déc, vol.89, issue.3, pp.16-22, 2003. ,
Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires, Basic Clin Pharmacol Toxicol. août, vol.115, issue.2, pp.193-200, 2014. ,
Eribulin mesylate, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, issue.21, pp.6615-6637, 2011. ,
Peripheral nerve damage associated with administration of taxanes in patients with cancer, Crit Rev Oncol Hematol. juin, vol.66, issue.3, pp.218-246, 2008. ,
Taxol induces caspase-10-dependent apoptosis, J Biol Chem. 3 déc, vol.279, issue.49, pp.51057-67, 2004. ,
Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1, J Clin Oncol Off J Am Soc Clin Oncol. 10 avr, vol.29, issue.11, pp.1472-1480, 2011. ,
Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms, J Adv Pract Oncol. juill, vol.4, issue.4, pp.204-219, 2013. ,
Taxane-induced peripheral neuropathy has good long-term prognosis: a 1-to 13-year evaluation, J Neurol. sept, vol.259, issue.9, pp.1936-1979, 2012. ,
Managing taxane toxicities. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, mars, vol.11, issue.3, pp.144-151, 2003. ,
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer, J Clin Oncol Off J Am Soc Clin Oncol. 20 août, vol.23, issue.24, pp.5542-51, 2005. ,
Taxane induced neuropathy in patients affected by breast cancer: Literature review, Crit Rev Oncol Hematol, vol.96, issue.1, pp.34-45, 2015. ,
Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties, Crit Rev Oncol Hematol, vol.40, issue.2, pp.159-73, 2001. ,
Vincristine-induced peripheral neuropathy in pediatric cancer patients, Am J Cancer Res, vol.6, issue.11, pp.2416-2446, 2016. ,
Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies, Expert Opin Drug Metab Toxicol. mars, vol.10, issue.3, pp.483-94, 2014. ,
Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy, J Clin Med Res. août, vol.6, issue.4, pp.252-60, 2014. ,
Vincristine: Can its therapeutic index be enhanced? Pediatr Blood Cancer. 15 déc, vol.53, pp.1180-1187, 2009. ,
DOI : 10.1002/pbc.22161
Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia, Med Sci Monit Int Med J Exp Clin Res. 7 juin, vol.21, pp.1656-61, 2015. ,
Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine, Biochemistry. 28 mai, vol.35, issue.21, pp.6806-6820, 1996. ,
Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas, Cancer. 15 mai, vol.73, issue.10, pp.2515-2524, 1994. ,
Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma, Eur J Neurol. juill, vol.14, issue.7, pp.826-834, 2007. ,
Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report, J Neurosurg Spine. mars, vol.6, issue.3, pp.280-283, 2007. ,
DOI : 10.3171/spi.2007.6.3.280
Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer. Pediatr Blood Cancer, janv, vol.64, issue.1, pp.180-187, 2017. ,
A practical update on the use of bortezomib in the management of multiple myeloma, The Oncologist. janv, vol.11, issue.1, pp.51-61, 2006. ,
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature, Blood. 1 sept, vol.112, issue.5, pp.1593-1602, 2008. ,
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies, Cancer Treat Rev. déc, vol.31, issue.8, pp.591-602, 2005. ,
Chemotherapy-induced neuropathy: A comprehensive survey, Cancer Treat Rev. août, vol.40, issue.7, pp.872-82, 2014. ,
DOI : 10.1016/j.ctrv.2014.04.004
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature, Cancer. 1 sept, vol.110, issue.5, pp.1042-1051, 2007. ,
Update on Chemotherapy-Induced Peripheral Neuropathy, Curr Neurol Neurosci Rep. juin, vol.17, issue.6, p.47, 2017. ,
DOI : 10.1007/s11910-017-0757-7
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations, Haematologica. févr, vol.95, issue.2, pp.311-320, 2010. ,
DOI : 10.3324/haematol.2009.012674
URL : http://www.haematologica.org/content/95/2/311.full.pdf
Thalidomide as a novel therapeutic agent: new uses for an old product, Drug Discov Today. 15 janv, vol.10, issue.2, pp.107-121, 2005. ,
Thalidomide and lenalidomide in multiple myeloma, Best Pract Res Clin Haematol, vol.19, issue.4, pp.769-80, 2006. ,
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma, Eur J Haematol. mars, vol.74, issue.3, pp.212-218, 2005. ,
Central and peripheral nervous system toxicity of common chemotherapeutic agents, Cancer Chemother Pharmacol. avr, vol.63, issue.5, pp.761-768, 2009. ,
Management of thalidomide toxicity, J Support Oncol, vol.1, issue.3, pp.194-205, 2003. ,
Chemotherapy-induced neuropathies-a growing problem for patients and health care providers, Brain Behav, vol.7, issue.1, p.558, 2017. ,
Longterm outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects, Leuk Res. sept, vol.33, issue.9, pp.145-149, 2009. ,
Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis, Oncotarget. 19 déc, vol.8, issue.67, pp.112076-84, 2017. ,
,
, Bull Cancer (Paris). sept, vol.102, issue.9, pp.737-785, 2015.
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy, Breast Cancer Res Treat. juill, vol.140, issue.2, pp.341-51, 2013. ,
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy, Int J Womens Health, vol.7, pp.47-58, 2015. ,
Marine drugs for cancer: surfacing biotechnological innovations from the oceans. Clin Sao Paulo Braz, vol.20, p.482, 2018. ,
Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice, Cancer Res. 1 juin, vol.71, issue.11, pp.3952-62, 2011. ,
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy, Neurotoxicology. juill, vol.37, pp.231-240, 2013. ,
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy, J Clin Oncol Off J Am Soc Clin Oncol. 10 juill, vol.31, issue.20, pp.2627-2660, 2013. ,
TwoYear Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715), J Natl Cancer Inst. 18 janv, 2018. ,
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, doubleblind, placebo-controlled study, Cancer. 15 juin, vol.120, issue.12, pp.1890-1897, 2014. ,
N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. mai, vol.14, issue.5, pp.484-491, 2006. ,
The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.19, pp.1769-77, 2011. ,
Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis, Contemp Oncol Poznan Pol, vol.20, issue.3, pp.237-278, 2016. ,
Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial, Int J Prev Med, vol.6, p.104, 2015. ,
Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma, J Cancer Res Clin Oncol. mars, vol.130, issue.3, pp.153-60, 2004. ,
Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer, N Engl J Med. 11 janv, vol.322, issue.2, pp.89-94, 1990. ,
A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer, Gynecol Oncol, vol.67, issue.2, pp.172-179, 1997. ,
Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel, Eur J Cancer Care (Engl). janv, vol.18, issue.1, pp.78-83, 2009. ,
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients, The Oncologist. mars, vol.12, issue.3, pp.312-321, 2007. ,
Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy, Ann Pharmacother. oct, vol.42, issue.10, pp.1481-1486, 2008. ,
Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial, BMC Cancer. 15 août, vol.12, p.355, 2012. ,
The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial, Biomark Res, vol.4, p.13, 2016. ,
Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer, Neurology. 6 sept, vol.77, issue.10, pp.987-95, 2011. ,
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen, Int J Clin Oncol. août, vol.16, issue.4, pp.322-329, 2011. ,
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study, Int J Clin Oncol. août, vol.20, issue.4, pp.767-75, 2015. ,
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy, Cancer Chemother Pharmacol. déc, vol.72, issue.6, pp.1283-90, 2013. ,
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 15 juin, vol.10, issue.12, pp.4055-61, 2004. ,
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity, J Clin Oncol Off J Am Soc Clin Oncol. 1 sept, vol.25, issue.25, pp.4028-4037, 2007. ,
Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy, Asia Pac J Clin Oncol. déc, vol.6, issue.4, pp.270-277, 2010. ,
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7, J Clin Oncol Off J Am Soc Clin Oncol. 1 févr, vol.29, issue.4, pp.421-428, 2011. ,
Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance), J Clin Oncol Off J Am Soc Clin Oncol. 1 avr, vol.32, issue.10, pp.997-1005, 2014. ,
Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review, Oncology, vol.90, issue.6, pp.299-306, 2016. ,
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.13, pp.797-805, 2005. ,
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy, Clin Cancer Res Off J Am Assoc Cancer Res. 1 mars, vol.11, issue.5, pp.1890-1898, 2005. ,
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study, Invest New Drugs. avr, vol.25, issue.2, pp.173-80, 2007. ,
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. févr, vol.24, issue.2, pp.547-53, 2016. ,
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatininduced neurotoxicity, Clin Colorectal Cancer. juill, vol.6, issue.2, pp.146-51, 2006. ,
Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. The Oncologist, vol.22, pp.1154-105, 2017. ,
Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms, Anticancer Res. juill, vol.29, issue.7, pp.2601-2607, 2009. ,
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy, Pain. juill, vol.98, issue.1-2, pp.195-203, 2002. ,
Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a singlecenter retrospective case-control study, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. mai, vol.24, issue.5, pp.2085-91, 2016. ,
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial, Ann Oncol Off J Eur Soc Med Oncol. janv, vol.23, issue.1, pp.200-205, 2012. ,
MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. mars, vol.24, issue.3, pp.1071-1079, 2016. ,
Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial, Int J Clin Oncol, vol.20, issue.5, pp.866-71, 2015. ,
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapyinduced painful peripheral neuropathy: a randomized clinical trial, JAMA. 3 avr, vol.309, issue.13, pp.1359-67, 2013. ,
A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy, Contemp Clin Trials. juill, vol.70, pp.135-143, 2018. ,
Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy, Chin J Cancer Res Chung, vol.29, issue.5, pp.411-419, 2017. ,
Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms, J Pain Symptom Manage. janv, vol.35, issue.1, pp.31-40, 2008. ,
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer, vol.110, pp.2110-2118, 2007. ,
Role of pregabalin in treatment of oxaliplatininduced sensory neuropathy, Anticancer Res. juill, vol.30, issue.7, pp.2927-2960, 2010. ,
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 15 juin, vol.112, issue.12, pp.2802-2810, 2008. ,
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, juin, vol.19, issue.6, pp.833-874, 2011. ,
Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist, Support Care Cancer Off J Multinatl Assoc Support Care Cancer. sept, vol.23, issue.9, pp.2769-77, 2015. ,
High-dose 8% capsaicin patch in treatment of chemotherapyinduced peripheral neuropathy: single-center experience, Med Oncol Northwood Lond Engl. 17 août, vol.34, issue.9, p.162, 2017. ,
A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain, J Pain Symptom Manage. janv, vol.47, issue.1, pp.166-73, 2014. ,
New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy, Asia-Pac J Oncol Nurs. mars, vol.3, issue.1, pp.73-85, 2016. ,
A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer Off J Multinatl Assoc Support Care Cancer, vol.25, pp.3407-3423, 2017. ,
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial, J Natl Cancer Inst. 1 févr, vol.110, issue.2, pp.141-149, 2018. ,
Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review, Crit Rev Oncol Hematol. févr, vol.98, pp.325-359, 2016. ,
A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. Evid-Based, Complement Altern Med ECAM, p.516916, 2013. ,